A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy Adults

Phase 1/2 Recruiting 120 enrolled GC Biopharma Corp

RandomizedParallel-groupTriple-blindPrevention

Summary

This clinical trial consists of two parts: Part 1, which explores safety, and Part 2, which examines both safety and efficacy (immunogenicity). Part 1 is a single-center, open-label, single-group study, while Part 2 is designed as a multicenter, double-blind, randomized, active-controlled trial.

Timeline

Start: 2025-06-05
Primary completion: 2026-05
Completion: 2026-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Boostrix	Vaccine	0.5 ml	Intramuscular
Subject	GC3111B	Vaccine	0.5 ml	Intramuscular

Indications

No indication recorded.